CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CENTURY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)

01/13/2022 | 08:32am EDT

Item 1.01 Entry into a Material Definitive Agreement.

Century Therapeutics, Inc. (the "Company") is party to an exclusive license with FUJIFILM Cellular Dynamics Inc., ("FCDI"), dated September 18, 2018, as amended, with respect to certain patents and know-how related to the differentiation of induced pluripotent stem cells ("iPSCs") into immune-effector cells in the field of cancer immunotherapeutics (the "Differentiation License") and a non-exclusive license with FCDI, also dated September 18, 2018, as amended, with respect to certain patents and know-how related to the reprogramming of human somatic cells to iPSCs in the field of cancer immunotherapeutics (the "Reprogramming License," and together with the Differentiation License, the "FCDI Agreements").

On January 7, 2022, the Company and FCDI entered into a letter agreement (the "Letter Agreement"), which amends each of the FCDI Agreements such that (i) the definition of Territory under each of the FCDI Agreements, for purposes of the sublicenses under the FCDI Agreements pursuant to the Company's Research Collaboration and License Agreement with Bristol-Myers Squibb Company ("BMS") dated January 7, 2022 (the "Collaboration Agreement") includes Japan, (ii) the licenses granted to the Company and its affiliates under the FCDI Agreements are sublicensable to BMS, including with respect to Japan and (iii) BMS is not subject to grant-back and option provisions under the Reprogramming License.

Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, the Company will pay to FCDI (i) an upfront payment of $10 million, (ii) a percentage of any milestone payments received by the Company under the Collaboration Agreement in respect of achievement of development or regulatory milestones specific to Japan, and (iii) a percentage of all royalties received by the Company under the Collaboration Agreement in respect of sales of products in Japan.

The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Letter Agreement, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2022.

© Edgar Online, source Glimpses

All news about CENTURY THERAPEUTICS, INC.
05/17Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Ov..
MT
05/16Century Therapeutics Q1 Net Loss Narrows; Posts Revenue of $1.1 Million
MT
05/16CENTURY THERAPEUTICS, INC. Management's discussion and analysis of financial condition..
AQ
05/16Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
05/12William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating
MT
05/10CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/02Century Therapeutics to Present at the ASGCT 25th Annual Meeting
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 272 M - -
Net income 2022 -135 M - -
Net cash 2022 127 M - -
P/E ratio 2022 -3,70x
Yield 2022 -
Capitalization 501 M 501 M -
EV / Sales 2022 1,38x
EV / Sales 2023 16,3x
Nbr of Employees 179
Free-Float 63,4%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,51 $
Average target price 24,60 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-47.04%494
MODERNA, INC.-46.35%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.46%38 185
SEAGEN INC.-9.68%26 255
ICON PUBLIC LIMITED COMPANY-30.22%17 418